Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EHSG-KF versus meshed split-thickness skin graft in children with severe burns
NL-OMON59223Phase 2Completed
- Sponsor
- CUTISS
- Start
- Jan 2019
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of denovoSkin in burn injury (2 arms), sponsored by CUTISS. Primary endpoint: Primary efficacy endpoint. Started Jan 2019; status: completed.
02
Drugs
denovoSkin
03
Conditions
burn injury
Beyond the preview
Go deeper on NL-OMON59223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59223.